Intrexon Corp (NASDAQ:XON) CEO Randal J. Kirk acquired 60,530 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The shares were bought at an average cost of $4.69 per share, with a total value of $283,885.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
XON stock opened at $4.70 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 4.29 and a current ratio of 3.91. The stock has a market cap of $747.55 million, a price-to-earnings ratio of -3.43 and a beta of 2.18. Intrexon Corp has a 1-year low of $3.95 and a 1-year high of $19.94.
Intrexon (NASDAQ:XON) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.28) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.28). The firm had revenue of $23.30 million for the quarter, compared to analyst estimates of $32.12 million. Intrexon had a negative return on equity of 26.52% and a negative net margin of 363.14%. The company’s revenue for the quarter was down 41.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.36) earnings per share. Analysts predict that Intrexon Corp will post -1.17 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/23/randal-j-kirk-acquires-60530-shares-of-intrexon-corp-xon-stock.html.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Featured Article: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.